Treatment by allogeneic BMT has resulted in an increasingly large cohort of long-term survivors. However, the price of this success, as in organ transplant recipients, is the risk of cutaneous cancers.
The risk of skin melanoma in allogeneic transplant recipients is 3-fold higher than in renal transplant patients. 3 Conditioning with total-body irradiation increases the risk of BCC (HR, 3.9 (95% CI, 2.6-6.8)). 3 GvHD is an independent risk factor for skin cancers after BMT. [4] [5] [6] [7] Curtis et al. 5 showed that the risk for SCC among bone marrow transplant recipients who developed chronic GvHD was nearly 3-fold higher (relative risk (RR) = 2.79) than in patients with no acute and no chronic GvHD. Major risk factors for the development of SCC were long duration of chronic GvHD therapy (P o 0.001), the use of azathioprine, particularly when combined with cyclosporine and steroids (P o 0.001), and severe chronic GvHD (P = 0.004). No increase in risk was found for BCC or MM. 5 The large series reporting skin carcinoma risk in hematologic patients are retrospective studies based on national registries. In consequence, there are no data on the severity of the lesions. Most patients experiencing GvHD are referred to dermatologists because of the prevalence of skin symptoms. We decided therefore to characterize the skin cancers observed in this patient population.
We investigated the charts of patients who were bone marrow transplanted after 1983 in the hematology and pediatric departments of our institution. To have a sufficient follow-up period, we limited our search to patients transplanted before 2009. Between 1983 and 2009, 480 patients were transplanted. One-hundred and sixty-two developed cutaneous GvHD. We contacted these patients by phone to be reexamined. Many declined because they were deterred by the prospect of further medical care considering themselves as definitively cured, some had moved away from the region and were lost to follow-up, and others had died. Finally, 31 patients accepted the invitation to be examined.
The medical history of the patients since BMT was recorded and skin and mucosa (oral and genital) were examined by a trained dermatologist. No skin or mucosal cancers were detected. Four patients, two females and two males (12.9%), had developed a total of 42 secondary skin carcinomas (36 BCC and 6 SCC). No melanoma was recorded. The median age of these patients at the time of BMT was 29 years (range, 6-55). Initial diagnosis was acute lymphocytic leukemia (1one case), acute myeloblastic leukemia (two cases) and mantle cell lymphoma (one case). None of these patients had a history of carcinoma before transplantation. The median age at skin carcinoma diagnosis was 37 years (range, 20-58) with a median interval of 8.5 years (3-14) after bone transplantation.
The first patient, a woman, bone marrow-transplanted at the age of 6, had developed 30 BCC on the face, scalp and trunk 14 years after transplant. The second was transplanted at the age of 55 and had developed three SCC on his face 3 years after transplantation. The third was a 49-year-old woman, transplanted 11 years before, who had developed six BCC, one Bowen's The small number of patients included in this study prevents us from establishing a statistical analysis of carcinoma incidence. Our sample may have been enriched with patients having severe forms of skin cancers and who consequently felt more concerned by such a study. In addition, the incidence of skin carcinomas in our series was 12.9%, whereas the cumulative incidence of these pathologies in large series is o 7% 20 years after transplantation. 5 We can nevertheless draw some conclusions regarding the clinical presentation of our patients, which was remarkable in many respects. First, most of the patients had a surprisingly high number of carcinoma lesions despite the absence of other skin risk factors such as excessive sun exposure. Second, skin lesions were observed in three patients who had been free of skin GvHD for several years. Third, skin and mucosal cancers appeared not only in the period immediately following transplantation but also 410 years after. None of the patients' lesions were metastatic. Metastatic cancers after marrow transplantation have been occasionally reported, with either skin 8 or mucosal carcinoma. 9 Research for the association between HPV infection and oral carcinomas in bone marrow transplanted patients gave controversial results 10, 11 and no data have been published concerning skin carcinomas. In our patients, including patient 4 with lip carcinoma, no HPV was detected in tumor cells suggesting that the role of the virus in carcinogenesis is not as constant as it is in organ transplanted patients. This difference between the two transplanted populations may be due to the lower duration of immunosuppression after bone marrow transplant. However, these data should be confirmed by additional studies.
In conclusion, the risk of skin cancer should be seriously taken into account during follow-up of patients after bone marrow transplantation. Our series suggests that these cancers can be highly relapsing, even several years after transplantation and even after resolution of GvHD. We would like to encourage our hematologist colleagues to have their marrow-transplanted patients examined annually by a dermatologist throughout life. Most skin carcinomas are induced by ultraviolet exposure and hence these patients, like organ transplant recipients, should receive advice and guidance about effective sun protection.
